Maladie de Hodgkin : faut-il sélectionner des patients à haut risque et intensifier la chimiothérapie ? = Hodgkin's disease: high-risk patients selection for chemotherapy intensification?CARDE, P.Bulletin du cancer. 1995, Vol 82, Num 8, pp 637-649, issn 0007-4551Article

Hodgin's disease. I: Identification and classificationCARDE, P.BMJ. British medical journal (International ed.). 1992, Vol 305, Num 6845, pp 99-102, issn 0959-8146Article

Chemotherapy of Hodgkin's diseaseCARDE, P.Nouvelle revue française d'hématologie. 1990, Vol 32, Num 2, pp 169-173, issn 0029-4810, 5 p.Article

ASSOCIATIONS ENTRE LES RADIATIONS IONISANTES ET CERTAINS ANTIMITOTIQUES: EFFETS AU NIVEAU CELLULAIRELAVAL F; CARDE P; MICHEL S et al.1981; BULL. CANCER; ISSN 0007-4551; FRA; DA. 1981; VOL. 68; NO 2; PP. 116-120; ABS. ENG; BIBL. 14 REF.Article

Maladie de Hodgkin : pourquoi faut-il la radiothérapie dans les stades étendus III-IV ? = Hodgkin's disease : Why is irradiation needed in advanced stages III-IV?CARDE, P.Cancer radiothérapie. 1999, Vol 3, pp 137s-141s, issn 1278-3218, SUP1Conference Paper

Diagnostic proceduresCARDE, P.Baillière's clinical haematology. 1996, Vol 9, Num 3, pp 479-501, issn 0950-3536Article

Who are the high-risk patients with Hodgkin's disease ?CARDE, P.Leukemia. 1996, Vol 10, pp S62-S68, issn 0887-6924, SUP2Conference Paper

La chimiothérapie en perfusion intraveineuse prolongée: revue générale des bases théoriques et résultats = Continuous intravenous infusion of chemotherapy: theorical aspects and resultsGANEM, G; CARDE, P; GOUYETTE, A et al.Bulletin du cancer. 1985, Vol 72, Num 6, pp 491-505, issn 0007-4551Article

Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity?CARDE, P; KOSCIELNY, S; BONVIN, N et al.Annals of oncology. 2002, Vol 13, pp 86-91, issn 0923-7534, SUP1Conference Paper

Le rôle de la radiothérapie dans les formes localisées de maladie de Hodgkin en 1999 : limitations et perspectives = The role of radiation therapy for limited stage (I and II) Hodgkin's disease : limitations and perspectivesCOSSET, J. M; FERME, C; HENRY-AMAR, M et al.Cancer radiothérapie. 1999, Vol 3, Num 2, pp 112-118, issn 1278-3218Article

VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's diseaseRIBRAG, V; NASR, F; PICO, J. L et al.Bone marrow transplantation (Basingstoke). 1998, Vol 21, Num 10, pp 969-974, issn 0268-3369Article

Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease : the H6 twin randomized trials from the European organization for research and treatment of cancer lymphoma cooperative groupCARDE, P; HAGENBEEK, A; SOMERS, R et al.Journal of clinical oncology. 1993, Vol 11, Num 11, pp 2258-2272, issn 0732-183XArticle

Phase II study of cytarabine in Hodgkin's diseaseTHOMAS, J; DE PAUW, B; HAGENBEEK, A et al.European journal of cancer (1990). 1992, Vol 28A, Num 4-5, pp 857-859, issn 0959-8049Article

Séraspénide (acétylSDKP) : étude en phase I-II d'un inhibiteur de l'hématopoïèse la protégeant de la toxicité de monochimiothérapies aracytine et ifosfamide = Phase I-II trial of seraspenide: a suppressor of myelopoiesis protects against cytarabine and ifosfamide monochemotherapy myelotoxicityCARDE, P; CHASTANG, C; GARCIA-GIRALT, E et al.Comptes rendus de l'Académie des sciences. Série 3, Sciences de la vie. 1992, Vol 315, Num 13, pp 545-550, issn 0764-4469Article

Radiotherapy versus combined modality in early stagesSPECHT, L; CARDE, P; MAUCH, P et al.Annals of oncology. 1992, Vol 3, pp S77-S81, issn 0923-7534, SUP4Conference Paper

Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocolsHENRY-AMAR, M; HAYAT, M; VAN DER SCHUEREN, E et al.International journal of radiation oncology, biology, physics. 1990, Vol 19, Num 5, pp 1155-1157, issn 0360-3016Article

Blastoid mantle cell lymphoma: evidence for nonrandom cytogenetic abnormalities additional to t(11;14) and generation of a mouse modelM'KACHER, R; FARACE, F; CARDE, P et al.Cancer genetics and cytogenetics. 2003, Vol 143, Num 1, pp 32-38, issn 0165-4608, 7 p.Article

Thrombotic microangiopathy: a new dose-limiting toxicity of high-dose sequential chemotherapyVANTELON, J. M; MUNCK, J. N; BOURHIS, J. H et al.Bone marrow transplantation (Basingstoke). 2001, Vol 27, Num 5, pp 531-536, issn 0268-3369Article

The tetrapeptide Acetyl-N-Ser-Asp-Lys-Pro (goralatide) protects from doxorubicin-induced toxicity : Improvement in mice survival and protection of bone marrow stem cells and progenitorsMASSE, A; RAMIREZ, L. H; SAINTENY, F et al.Blood. 1998, Vol 91, Num 2, pp 441-449, issn 0006-4971Article

Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy : Interim results from the ongoing EORTC-LCG and GPMC phase III trialRAEMAEKERS, J; BURGERS, M; VAN HOOF, A et al.Annals of oncology. 1997, Vol 8, pp 111-114, issn 0923-7534, SUP1Conference Paper

Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphomaMEERWALDT, J. H; CARDE, P; HAGENBEEK, A et al.Annals of oncology. 1997, Vol 8, pp 67-70, issn 0923-7534, SUP1Conference Paper

Essai randomisé avec placebo de myéloprotection par le goralatide^* des patients présentant un carcinome épidermoïde des voies aérodigestives supérieures ou de l'œsophage, traités par l'association carboplatine-5 fluorouracile = Randomized trial of myeloprevention by goralatide vs placebo in patients with head and neck squamous cell carcinoma, treated by carboplatin-fluorouracilCAPPELAERE, P; HECQUET, B; ROLLAND, F et al.Bulletin du cancer. 1995, Vol 82, Num 9, pp 732-737, issn 0007-4551Article

Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin diseaseHENRY-AMAR, M; FRIEDMAN, S; BRON, D et al.Annals of internal medicine. 1991, Vol 114, Num 5, pp 361-365, issn 0003-4819, 5 p.Article

Classical external indwelling central venous catheter versus totally implanted venous access systems for chemotherapy administration: a randomized trial in 100 patients with solid tumorsCARDE, P; OSSET-DELAIGUE, M. F; LAPLANCHE, A et al.European journal of cancer & clinical oncology. 1989, Vol 25, Num 6, pp 939-944, issn 0277-5379Article

Phase II trial of combined 5-fluorouracil plus doxorubicin plus cisplatin (FAP regimen) in advanced gastric carcinomaROUGIER, P; DROZ, J. P; THEODORE, C et al.Cancer treatment reports. 1987, Vol 71, Num 12, pp 1301-1302, issn 0361-5960Article